Patricia Martin
As Chief Operating Officer, Patricia is responsible for LimmaTech’s vaccine clinical programs. She joined GlycoVaxyn in 2014 in the Clinical Department and became part of LimmaTech’s Executive Management team in 2019 as Vice President of Clinical and Regulatory Affairs and later as Managing Director. Prior to GlycoVaxyn, Patricia held various roles in clinical research in several biotech companies and CROs. In her over 15 years of industrial experience, she has acquired significant expertise in diverse vaccine and therapeutic clinical indications and has overseen studies ranging from Phase I to Phase IV. Patricia has a degree in Biochemistry from the National University of Cordoba, Argentina. After relocating to Switzerland, she received her PhD in Natural Science from the University of Zürich.